ReviewInternational journal of molecular sciences2022
The Downstaging Concept in Treatment-Resistant Depression: Spotlight on Ketamine.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Neurodegenerative and Cognitive Consequences of Long COVID.International journal of molecular sciences · 2026Review
- Anhedonia nonresponse to short-term ketamine administration for treatment-resistant bipolar depression.Therapeutic advances in psychopharmacology · 2026Article
- Appetite measures during ketamine administration in treatment-resistant mood disorders: a naturalistic study.Frontiers in nutrition · 2026Article
- Non-response to short-term ketamine use for treatment-resistant depression.Pharmacological reports : PR · 2025Observational
- Long-Term Outcomes in Patients With Treatment-Refractory Depression Receiving Intravenous Ketamine and Intranasal Esketamine: An Observational Study.The Journal of clinical psychiatry · 2025Observational
- Treating chronic pain with low dose ketamine and adjunct therapies within a biopsychosocial approach: a case series.Frontiers in pain research (Lausanne, Switzerland) · 2025Article
- Exploring the Relationship between Mood Disorders and Coexisting Health Conditions: The Focus on Nutraceuticals.Brain sciences · 2023Review
- Inflammation and Treatment-Resistant Depression from Clinical to Animal Study: A Possible Link?Neurology international · 2023Article
- Ketamine as Add-On Treatment in Psychotic Treatment-Resistant Depression.Brain sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Treatment-resistant depression is a pleomorphic phenomenon occurring in 30% of patients with depression. The chance to achieve remission decreases with every subsequent episode. It constitutes a significant part of the global disease burden, causes increased morbidity and mortality, and is associated with poor quality of life. It involves multiple difficult-to-treat episodes, with increasing resistance over time. The concept of staging captures the process of changes causing increasing treatment resistance and global worsening of functioning in all areas of life. Ketamine is a novel rapid-acting antidepressant with neuroplastic potential. Here, we argue that ketamine use as an add-on treatment of resistant major depressive disorder, based on its unique pharmacological properties, can reverse this process, give hope to patients, and prevent therapeutic nihilism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.